Should adjuvant tamoxifen therapy be stopped at 5 years?

Cancer Journal from Scientific American

Volumn 2, Issue 3, 1996, Pages 140-150

  Bilimoria, Malcolm M ^a   Assikis, Vasilios J ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Endometrial carcinoma; Tamoxifen

Indexed keywords

LIPID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ANIMAL; ARTICLE; BLOOD; BONE; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; NEOPLASM; OSTEOPOROSIS; RISK ASSESSMENT; TIME;

ANIMALS; BONE AND BONES; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPIDS; NEOPLASMS; OSTEOPOROSIS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS;

EID: 0000396336     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Jordan VC. The development of tamoxifen for breast cancer therapy. In: Jordan VC, ed. Long-term tamoxifen treatment for breast cancer. 1st ed. Madison, WI: The University of Wisconsin Press, 1994:3-26.
2. DeGregorio MW. Is tamoxifen chemoprevention worth the risk in healthy women? J Natl Inst Health Res 1992;4:84.
3. Love RR. Tamoxifen in healthy premenopausal and postmenopausal women: different risks and benefits. J Natl Cancer Inst 1994;86:62-63.
4. Jordan VC. Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 1995;208:144-149.
5. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-517.
6. Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1984;1:1256-1260.
7. Ribeiro G, Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7 year results. Eur J Cancer Clin Oncol 1985;21:897-900.
8. Rose C, Thorpe SM, Andersen KW et al. Beneficial effects of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen levels. Lancet 1985;1:16-19.
9. Hubay CA, Gordon NH, Crowe JP et al. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in Stage II breast cancer: seventy-two month followup. Surgery 1984;96: 61-72.
10. Jordan VC, Allen KE. Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-251.
11. Jordan VC. Use of DMBA induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endo Related Cancer 1978:49-55.
12. Jordan VC, Dix CJ, Allen KE. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE, eds. Adjuvant Therapy of Cancer II. Orlando, Fla: Grune & Stratton 1979:19-26.
13. Jordan VC, Naylor KE, Dix CJ, Prestwich G. Antioestrogen action in experimental breast cancer. In: Endocrine Treatment of Breast Cancer. Recent Results in Cancer Research 71. Heidelberg: Springer-Verlag 1980:30-44.
14. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Lancet 1985;i: 836-839.
15. Breast Cancer Trials Committee. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet 1987;ii: 171-175.
16. Boccardo F, Rubagotti A, Bruzzi P et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive estrogen receptor-positive breast cancer patients: Results of a multicenter Italian study. J Clin Oncol 1990;8:1310-1320.
17. Wallgren A, Baral E, Carstensen J et al. Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones SE, Salmon SE, eds. Adjuvant Therapy of Cancer IV. 4th ed. Orlando, Fla: Grune and Stratton, 1984:331-338.
18. Rutqvist LE, Cedermark B, Glaus U et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 1987:10:255-266.
19. Fisher B, Brown A, Wolmark N et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987;106:649-654.
20. Tormey DC. Long-term adjuvant therapy with tamoxifen in breast cancer: How long is long? Ann Intern Med 1987;106:762-764.
21. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983;3:S73-S86.
22. Tormey DC, Jordan VC. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984;4:297-302.
23. Falkson HC, Gray R, Wolberg WH et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group Phase III Study. J Clin Oncol 1990;4:599-607.
24. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
25. Boring C, Squire T, Tong T et al. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
26. Fisher B, Costantino J, Redmond C et al. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989;320:479-484.
27. Palshof T, Mourisden HT, Daehnfeldt JL et al. Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Endo Rel Cancer 1985;M 17[suppl]:43-50.
28. Pritchard KI, Meakin JW, Boyd NF et al. Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: an update. Adjuvant Therapy of Cancer V. New York: Grune and Stratton, 1987:391-400.
29. Cummings RJ, Gray R, Davis TE et al. Tamoxifen versus placebo: Double-blind adjuvant trial in elderly women with stage II breast cancer. Proceedings of the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer. Bethesda, Md: NIH;1986:119-123.
30. Cancer Research Campaign, Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988;57:604-607.
31. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncologica 1992;31:259-263.
32. Ryden S, Ferno M, Moller T et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. Acta Oncologica 1992;31:271-274.
33. Mason BH, Holdaway IM, Benton NM et al. Detection of contralateral breast cancer by mammography in women with previous breast cancer and the impact of endocrine therapy. NZ Med J 1993;10:623-625.
34. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-1459.
35. Lobo RA, Pickar JH, Wild RA et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987-995.
36. Lindsey R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76: 290-295.
37. Grady D, Rubin SM, Pettiti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
38. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-1198.
39. Bush TL, Barret-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-1109.
40. Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984;53:853-857.
41. Fornander T, Rutqvist LE, Sjoberg HE et al. Long-term adjuvant ramoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990;8:1019-1024.
42. Fentimen IS, Caleffi M, Rodin A et al. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Clin Pract 1989;68:34-36.
43. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
44. Cuzick J, Allen D, Baum M et al. Long-term effects of tamoxifen. Eur J Cancer 1993;22:87-94.
45. Ward RL, Morgan G, Dalley D et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22:87-94.
46. Neal AJ, Evans K, Hoskin PJ. Does long-term administration of tamoxifen effect bone mineral density? Eur J Cancer 1993;29: 1971-1973.
47. Turken S, Siris E, Seldin D et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086-1088.
48. Kristensen B, Ejlertsen B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 1994;12:992-997.
49. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:334-346.
50. Bruning PF, Bonfrer JMG, Hart AM et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Card 1988;58:497-499.
51. Bertelli G, Pronzato P, Amaroro et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipid S and antithrombin III levels. Breast Cancer Res Treat 1988;12:307-310.
52. Bagdade JD, Wolter J, Subbaiah PV. Effects of tamoxifen on treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 1990;70:1132-1135.
53. Love RR, Wiebe D, Newcomb P et al. Effects of tamoxifen on cardiovascular factors in postmenopausal women. Ann Intern Med 1991;115:860-864.
54. Ingram D. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust NZ J Surg 1990;60:673-675.
55. Dnistrian AM, Schwartz MK, Greenberg EJ. Effects of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clinica Chimica Acta 1993;223:43-52.
56. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 1994;73:659-663.
57. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol 1988;4:5A-10A.
58. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br J Med 1991;303:435-437.
59. Saryaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-4010.
60. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48: 812-815.
61. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11: 485-490.
62. Assikis VJ, Jordan VC. Gynecological effects of tamoxifen and association with endometrial carcinoma. Int J Gynecol Obstet 1995;49:241-257.
63. National Cancer Institute: SEER Cancer Statistics Review 1973-1990. Document #93-2789. Bethesda, Md: National Cancer Institue, 1993.
64. Williams GM, Iatropoulos MJ, Djordjevic MV et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993;14:315-317.
65. Greaves P, Goonetilleke R, Nunn G et al. Two year carcinogenicity study of tamoxifen in Alderly Park, Wistar derived rats. Cancer Res 1993;53:3919-3924.
66. White INH, DeMalteis F, Davis A et al. Genotoxic potential of tamoxifen and analogs in female Fischer F344/n rats, DBA/2 and C57 BL/6 mice and in human HCL-5 cells. Carcinogenesis 1992;13:2197-2203.
67. Han X, Liehr LG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancel Res 1992;52:1360-1363.
68. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994;30A: 1714-1721.
69. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? Ann Oncol 1995;6:29-34.
70. Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in eaily breast cancer: occurrence of new primary cancers. Lancet 1989;ii:117-120.
71. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991;20:38-46.
72. Rutqvist LE, Johansson H, Signomklao T et al. Adjuvant tamoxifen for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-651.
73. Jordan VC. Tamoxifen and tumorigenicity: A predictable concern. J Natl Cancer Inst 1995;87:623-626.
74. Spicer D, Pike MC, Henderson BE. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 1991;4:49-62.
75. Grady D, Gebzedfadik T, Kezlikowski K, Ezustez V, Petitti D. Hormone replacement therapy and endometrial cancer risk. Obstet Gynecol 1995;85:304-313.
76. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
77. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988;20:311-314.
78. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiesrrogen administration. Cancer Res 1988;48:5183-5187.
79. Gottardis MM, Wagner RJ, Borden EC, Jordan VC. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 1989;49:4765-4769.
80. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. Inhibition of tamoxifen stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989;49:4090-4093.
81. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;15:3867-3873.
82. Howell A, DeFriend D, Robertson J, Blarney R, Walton P. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30.
83. Wolf DM, Jordan VC. A laboratory model to explain the survival advantages observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993;53:533-535.
84. Assikis VJ, Jordan VC. A realistic assessment of the association between tamoxifen and endometrial cancer. Endo Rel Cancer 1995;2:235-241.